02/02/2021 By Dr. Dan Platt
Summary: The Food and Drug Administration (FDA) has announced the approval of a new therapy combination for relapsed or refractory multiple myeloma. The combination of carfilzomib (Kyprolis), daratumumab (Darzalex), and dexamethasone (steroid) is now approved for use in patients who have received one to three prior lines of treatment.
Dr. Dan’s Takeaway: These drugs were all previously approved for relapsed or refractory multiple myeloma and have proven effectiveness and safety. This particular combination was already being used by oncologists, but now has explicit FDA support and positive data that supports its role as another treatment option.
Deskside with Dr. Dan
“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”
– Dan Platt, M.D.
Chief Medical Officer